Storia in 2 fonti

The New Billionaire Bet Isn't AI — It's Longevity Biotech

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping the future of aging research.

Raccontata da

forbes.com

theinformation.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

forbes.comStai leggendo1 mese fa

The New Billionaire Bet Isn't AI — It's Longevity Biotech

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping the future of aging research.

originale

theinformation.com1 mese fa

Longevity Startups Have a Conundrum: Can They Sell Longevity Drugs?

In many ways, these are the best of times for Silicon Valley’s buzziest crop of longevity startups and their pursuit of drugs that can reverse aging. NewLimit, a cell reprogramming company co-founded in 2022 by Coinbase…

Leggi questa versione → originale

Timeline cronologica

giovedì 11 giugno 2026·forbes.com
The New Billionaire Bet Isn't AI — It's Longevity Biotech
As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping the future of aging research.
sabato 13 giugno 2026·theinformation.com
Longevity Startups Have a Conundrum: Can They Sell Longevity Drugs?
In many ways, these are the best of times for Silicon Valley’s buzziest crop of longevity startups and their pursuit of drugs that can reverse aging. NewLimit, a cell…